Dr Anussara Prayongrat

Doctoral of Philosophy, Graduate School of Medicine
Hokkaido University, Japan
2019

Higher Graduate Diploma of Clinical Science
Radiology, Chulalongkorn University, Thailand
2013

Doctor of Medicine (First Class Honor)
Faculty of Medicine, Chulalongkorn University, Thailand
2009

Visiting scientist in Stereotactic Radiosurgery and Proton Therapy
The University of Texas MD Anderson Cancer Center, U.S.A.
2016

Diploma of Radiotherapy and Oncology
2013

Thai Medical License
2009

Lertbutsayanukul C, Pitak M, Ajchariyasongkram N, Rakkiet N, Seuree F, Prayongrat A. Long‐term patient‐rated cosmetic and satisfactory outcomes of early breast cancer treated with conventional versus hypofractionated breast irradiation with simultaneous integrated boost technique. Breast J. 2020; 00: 1–7.

Prayongrat A, Lertbutsayanukul C. Hypothyroidism after radiotherapy for nasopharyngeal carcinoma. Ann Nasopharynx Cancer. 2020;4:3.

Prayongrat A. (2019) Gastrointestinal cancer. In: Chaiwatanarat T., Chakkabat C. Sirisalipoch S. Saksornchai K. (eds) Radiology: Nuclear Medicine, Therapeutic Radiation and Oncology. pp449-469. Chulalongkorn University Press, Bangkok (Thai version only)

Prayongrat A. (2019) Pediatric cancer. In: Chaiwatanarat T., Chakkabat C. Sirisalipoch S. Saksornchai K. (eds) Radiology: Nuclear Medicine, Therapeutic Radiation and Oncology. pp 535-589. Chulalongkorn University Press, Bangkok (Thai version only)

Prayongrat A. (2019) Proton therapy in nasopharyngeal cancer. In: Chawalit L. (eds) Nasopharyngeal carcinoma. pp 290-298. Chulalongkorn University Press, Bangkok (Thai version only)

Johnstone G, Ghia A, Prayongrat A. External Beam Radiotherapy in the Treatment of Painful Bone Metastases. In: Gulati A, Puttanniah V, Bruel BM, Rosenberg WS, Hung JC editors. Essentials of Interventional Cancer Pain Management. Cham, Switzerland: Springer Nature; 2019. p. 339-52.

Ghia A, Prayongrat A. Vertebral body metastasis. In: Chang E, Brown PD, editors. Adult CNS Radiation Oncology: Principle and Practice. Cham, Switzerland: Springer International Publishing; 2018. p. 177-188.

Prayongrat A, Kobashi K, Ito YM, Katoh N, Tamura M, Dekura Y, Toramatsu C, Khorprasert C, Amornwichet A, Alisanant P, Shirato H, Shimizu S. The normal tissue complication probability model-based approach considering uncertainties for the selective use of radiation modality in primary liver cancer patients. Radiother Oncol. 2019;135:100–6.

Kitpanit S, Jittapiromsak N, Sriyook A, Prayongrat A, Kannarunimit D, Chakkabat C, Lertbutsayanukul C. Comparison between the seventh and eighth edition of the AJCC/UICC staging system for nasopharyngeal cancer integrated with pretreatment plasma Epstein-Barr virus DNA level in a non-Chinese population: secondary analysis from a prospective randomized trial. Jpn J Clin Oncol. 2019 Dec 27;49(12):1100-1113.

Lertbutsayanukul C, Kannarunimit D, Prayongrat A, Chakkabat C, Kitpanit S, Hansasuta P. Prognostic Value of Plasma EBV DNA for Nasopharyngeal Cancer Patients during Treatment with Intensity-modulated Radiation Therapy and Concurrent Chemotherapy. Radiol Oncol. 2018;52(2):195-203.

Lertbutsayanukul C, Kitpanit S, Prayongrat A, Kannarunimit D, Netsawang B, Chakkabat C. Validation of previously reported predictors for radiation-induced hypothyroidism in nasopharyngeal cancer patients treated with intensity-modulated radiation therapy, a post hoc analysis from a Phase III randomized trial. J Radiat Res. 2018;59(4):446-55.

Lertbutsayanukul C, Kannarunimit D, Netsawang B, Kitpanit S, Chakkabat C, Hansasuta P, Prayongrat A. Optimal plasma pretreatment EBV DNA cut-off point for nasopharyngeal cancer patients treated with intensity modulated radiation therapy. Jpn J Clin Oncol. 2018;48(5):467-75.

Sio TT, Prayongrat A, Zhang Y, Lin Q, Xu T, Liao Z, Yue J. The Road Less Traveled: Should We Omit Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer? Clin Lung Cancer. 2018 Jul;19(4):289-93.

Kobashi K, Prayongrat A, Kimoto T, Toramatsu C, Dekura Y, Katoh N, Shimizu S, Ito YM, Shirato H. Assessing the uncertainty in a normal tissue complication probability difference (∆NTCP): radiation-induced liver disease (RILD) in liver tumour patients treated with proton vs X-ray therapy. J Radiat Res. 2018 Mar 1;59(suppl_1):i50-7.

Prayongrat A, Umegaki K, van der Schaaf A, Koong AC, Lin SH, Whitaker T, McNutt T, Matsufuji N, Graves E, Mizuta M, Ogawa K, Date H, Moriwaki K, Ito YM, Kobashi K, Dekura Y, Shimizu S, Shirato H. Present developments in reaching an international consensus for a model-based approach to particle beam therapy. J Radiat Res. 2018;59(suppl_1):i72-6.

Shirato H, Le QT, Kobashi K, Prayongrat A, Takao S, Shimizu S, Giaccia A, Xing L, Umegaki K. Selection of external beam radiotherapy approaches for precise and accurate cancer treatment. J Radiat Res. 2018;59(suppl_1):i2-10.

Nishioka K, Prayongrat A, Ono K, Onodera S, Hashimoto T, Katoh N, Inoue T, Kinoshita R, Yasuda K, Mori T, Onimaru R, Shirato H, Shimizu S.Prospective study to evaluate the safety of the world-first spot-scanning dedicated, small 360-degree gantry, synchrotron-based proton beam therapy system. J Radiat Res. 2018;59(suppl_1):i63-71.

Lertbutsayanukul C, Prayongrat A, Kannarunimit D, Chakkabat C, Netsawang B, Kitpanit S. A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma. Strahlenther Onkol. 2018;194(5):375-85.

Prayongrat A, Tao R, Allen PK, Guha N, Rao G, Zhoa Z, Li J, Brown PD, Mcgovern S. Outcomes of stereotactic radiosurgery of brain metastases from neuroendocrine tumors. Neuro-Oncology Practice. 2018. 5(1). 37–45.

Prayongrat A, Xu C, Li H, Lin SH. Clinical outcomes of intensity modulated proton therapy and concurrent chemotherapy in esophageal carcinoma: a single institutional experience. Adv Radiat Oncol. 2017;2(3):301-7.

Lertbutsayanukul C, Tharavej C, Klaikeaw N, Prayongrat A, Lowanitchai C, Sriuranpong V. High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma. Thorac Cancer. 2017;8(3):219-28.

Lan M, Chen C, Huang Y, Tian L, Duan Z, Han F, Liao J, Deng M, Sio TT, Prayongrat A, Zheng L, Wu S, Lu T. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis. Sci Rep. 2017;7:42624.

Prayongrat A, Chakkabat C, Kannarunimit D, Hansasuta P, Lertbutsayanukul C. Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma. J Radiat Res. 2017;58(4):509-16.

Songthong (Prayongrat) A, Chakkabat C, Kannarunimit D, Lertbutsayanukul C. Efficacy of intensity-modulated radiotherapy with concurrent carboplatin in nasopharyngeal carcinoma. Radiol Oncol. 2015; 49(2):155-62.

Songthong (Prayongrat) A, Kannarunimit D, Chakkabat C, Lertbutsayanukul C. A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events. Radiat Oncol. 2015;10:166.